Minutes of the CVMP meeting 18-19 June 2024
Submitted by Anonymous (not verified) on 25 July 2024 - 14:11
Minutes of the CVMP meeting 18-19 June 2024
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 July 2024 to 3 July 2024
Submitted by Anonymous (not verified) on 25 July 2024 - 14:06
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 July 2024 to 3 July 2024
Human medicines European public assessment report (EPAR): Symtuza, darunavir,cobicistat,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/09/2017, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 25 July 2024 - 13:55
Human medicines European public assessment report (EPAR): Symtuza, darunavir,cobicistat,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/09/2017, Revision: 18, Status: Authorised
Chemistry of active substances (chemistry of new active substances) - Scientific guideline
Submitted by Anonymous (not verified) on 25 July 2024 - 12:11
Chemistry of active substances (chemistry of new active substances) - Scientific guideline
Draft guideline on the chemistry of active substances - Revision 1
Submitted by Anonymous (not verified) on 25 July 2024 - 12:05
Draft guideline on the chemistry of active substances - Revision 1
Human medicines European public assessment report (EPAR): Nulibry, fosdenopterin, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 25 July 2024 - 11:50
Human medicines European public assessment report (EPAR): Nulibry, fosdenopterin, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Prevymis, Letermovir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0455/2023
Submitted by Anonymous (not verified) on 25 July 2024 - 9:54
Opinion/decision on a Paediatric investigation plan (PIP): Prevymis, Letermovir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0455/2023
EMEA-000737-PIP02-11-M03
Submitted by Anonymous (not verified) on 25 July 2024 - 9:49
EMEA-000737-PIP02-11-M03
Vabysmo
Submitted by Anonymous (not verified) on 25 July 2024 - 8:55
Vabysmo
Human medicines European public assessment report (EPAR): Entecavir Accord, entecavir, Date of authorisation: 25/09/2017, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 24 July 2024 - 17:30
Human medicines European public assessment report (EPAR): Entecavir Accord, entecavir, Date of authorisation: 25/09/2017, Revision: 7, Status: Authorised